<DOC>
	<DOC>NCT00002175</DOC>
	<brief_summary>To evaluate the efficacy of dinitrochlorobenzene (DNCB) in patients with early HIV infection by monitoring immunologic parameters and serum HIV RNA. To facilitate the understanding of possible alterations in the immunological status of the HIV+ patient cohort.</brief_summary>
	<brief_title>Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Inclusion Criteria Patients must have: EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests. For HIV+ patients: Patients must fail to meet the AIDSdefining criteria. CD4 lymphocyte count between 200 500 cells/mm3. Exclusion Criteria Coexisting Condition: Excluded: Patients with obvious ultra violet(UV)irradiated skin damage in the treatment sites. Concurrent Medication: Excluded: Patients who are likely to commence antiretrovirals within the 6month study period. Patients using other immunomodulator therapies or other alternative therapies. Patients likely to require chemotherapy during the course of the study. Concurrent Treatment: Excluded: Patients who are likely to require significant UV light exposure during the study period. Patients who are likely to require radiation therapy during the course of the study. Prior Medication: Excluded: Prior exposure to DNCB. Patients who have used antiretroviral medications within the previous 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 1999</verification_date>
	<keyword>Cohort Studies</keyword>
	<keyword>RNA, Viral</keyword>
	<keyword>Administration, Cutaneous</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Dinitrobenzenes</keyword>
</DOC>